Get started
Surrozen, Inc.Surrozen, Inc.Surrozen, Inc.

Surrozen, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

SRZN trade ideas

SRZN great trend up this year then pullback can be bought LONGSRZN ona 30 minute chart is on a consistent trend up for three weeks with some minor normal corrections while underway. Now is one of those pullbacks waiting for an entry. Price is getting support from the first upper VWAP bandline confluent with the lower ascending support line of the megaphone pattern. A megaphone pattern documents increasing volatility in the price action. Volatility is profitable in trading the swings as a swing trade or even intraday. I will take a long trade here targeting the top of the pattern or about going from 12 to 15 being 25% upside.
NASDAQ:SRZNLong
by AwesomeAvani
SRZN a Penny biotech LONGSRZN has had good momentum. It has no revenues. Clinical trials but a lot of cash. SRZN has advanced trials underway for a product to treat alcoholic hepatitis presumably settling it down before it becomes irreversible cirrhosis (only for patients who are alcohol-free) and also useful for liver metabolic disorders from a genetic basis. SRZN has been trending up for a week with a bit of a pause in the middle of it. It picked up 60% of its price while breaking out through the anchored VWAP lines and the volume profile. The far greater market is the former. It is priced at 90 or more off it's all-time high of about $160. IF it picks up hype from the last clinical trial getting a report and a calendared review by the, SRZN could reach for that all time high. This is speculative and risky as are most biotechnology penny stocks. They are trading news and potential not current net revenues. A small position with room in the stop loss for the average range and volatility is best. This is a typical high risk higher potential reward type of trade.
NASDAQ:SRZNLong
by AwesomeAvani
Down with Surrozen. SRZNGoals 2.36, 2.08 . We are not in the business of getting every prediction right, no one ever does and that is not the aim of the game. The Fibonacci targets are highlighted in purple with invalidation in red. Fibonacci goals, it is prudent to suggest, are nothing more than mere fractally evident and therefore statistically likely levels that the market will go to. Having said that, the market will always do what it wants and always has a mind of its own. Therefore, none of this is financial advice, so do your own research and rely only on your own analysis. Trading is a true one man sport. Good luck out there and stay safe
NASDAQ:SRZNShort
by Rykin_Capital
$SRZNCommon stock and warrants to commence trading on Nasdaq on August 12, 2021 under the ticker symbols SRZN and SRZNW SOUTH SAN FRANCISCO, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) — Surrozen, Inc. (“Surrozen”), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced the completion of its business combination with Consonance-HFW Acquisition Corp. (“Consonance-HFW”), a special purpose acquisition company (“SPAC”) sponsored by entities affiliated with Consonance Capital Management. The resulting combined company will commence trading its shares on Nasdaq under the ticker symbol “SRZN” and its warrants under the ticker symbol “SRZNW” on August 12, 2021. The shareholders of Consonance-HFW approved the transaction at an extraordinary general meeting held on August 10, 2021, and the transaction was previously approved by Surrozen’s stockholders. Surrozen’s management team, led by President and Chief Executive Officer, Craig Parker, will continue to lead the combined company. Craig Parker, President and Chief Executive of Officer of Surrozen, commented, “We have long known the importance of the Wnt pathway as the body’s own mechanism for tissue repair but harnessing its promise for therapeutic applications remained out of reach for drug developers until recently. We believe Surrozen has the potential to unlock the promise of the Wnt pathway and transform treatment of multiple serious diseases.” He further commented, “The capital raised from the successful completion of this transaction, along with our strategy to accelerate the development of our innovative programs, will help us bring this vision to life.” Gad Soffer, Chief Executive Officer of Consonance-HFW, commented, “We are proud to partner with Surrozen in hopes of providing breakthrough therapies in areas of high unmet need.” He added, “By combining experienced industry leaders with an innovative approach to harness the therapeutic potential of the Wnt pathway, we believe Surrozen is well positioned in its efforts to transform treatments for serious diseases.” About this Transaction On April 15th, 2021, Surrozen, a privately held biotechnology company, entered into a definitive business combination agreement with Consonance-HFW, a special purpose acquisition company (SPAC) that was created for the purpose of entering into a business combination with a selected life sciences company. The description of the business combination contained herein is only a high-level summary and is qualified in its entirety by reference to the underlying documents filed with the U.S. Securities and Exchange Commission. A more detailed description of the terms of the transaction has been provided in a registration statement on Form S-4 filed with the U.S. Securities and Exchange Commission by Consonance-HFW. Transaction Advisors J.P. Morgan Securities LLC is acting as financial advisor to Consonance-HFW in connection with the business combination, and J.P. Morgan Securities LLC and BofA Securities are acting as placement agents on behalf of Consonance-HFW. Guggenheim Securities, LLC is acting as financial advisor and capital markets advisor to Surrozen, and Stifel, Nicolaus & Company, Incorporated is acting as capital markets advisor to Surrozen in the transaction. Goodwin Procter LLP is acting as legal counsel to Consonance-HFW, Cooley LLP is acting as legal counsel to Surrozen and Wilson Sonsini Goodrich & Rosati, P.C. is acting as legal counsel to the placement agents. About Consonance-HFW Acquisition Corp. Consonance-HFW Acquisition Corp. is a recently incorporated blank check company incorporated as a Cayman Islands exempted company and incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. It is led by Chairman Mitchell Blutt, M.D., Chief Executive Officer Gad Soffer, Chief Financial Officer Kevin Livingston and VP Business Development Joshua House. About Consonance Capital Management Consonance Capital Management was founded in 2007 with approximately $50 million of assets under management by Mitchell Blutt, Benny Soffer and Kevin Livingston. As of March 31, 2021, the fund has grown to approximately $1 billion in assets under management and focuses on equity investments in life sciences companies, with an emphasis on small and mid-cap life sciences companies. About Surrozen Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with potential application across multiple disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas and central nervous system.
NASDAQ:SRZNLong
by BADQOMOCAWGOWLD